Publications by authors named "Mark Harries"

Claim this Profile
S
Systematic review of checkpoint inhibitor-induced epidermal necrolysis.
Rebecca Creamer, Freya Hamar-Davies, Mark Harries, Daniel Creamer

J Eur Acad Dermatol Venereol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Johannes R Björk, Laura A Bolte, Andrew Maltez Thomas, Karla A Lee, Niccolo Rossi, Mark Harries

Nat Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced Triple-Negative Breast Cancer.
Grisma Patel, Alison Prince, Mark Harries

Semin Oncol Nurs· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Laura A Bolte, Karla A Lee, Johannes R Björk, Emily R Leeming, Marjo J E Campmans-Kuijpers, Mark Harries

JAMA Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports.
Ammara Masood, Amanda Mootoo, Panayiotis Maghsoudlou, David D'Cruz, Krishnie Srikandarajah, Mark Harries

Autoimmun Rev· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
Alessia Visconti, Niccolò Rossi, Helena Deriš, Karla A Lee, Maja Hanić, Mark Harries

BMC Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma.
Niccolò Rossi, Karla A Lee, Maria V Bermudez, Alessia Visconti, Andrew Maltez Thomas, Mark Harries

EBioMedicine· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
Amanda Fitzpatrick, Marjan Iravani, Adam Mills, Lucy Childs, Thanussuyah Alaguthurai, Mark Harries

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Karla A Lee, Andrew Maltez Thomas, Laura A Bolte, Johannes R Björk, Laura Kist de Ruijter, Mark Harries

Nat Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
Leticia Monin, Adam G Laing, Miguel Muñoz-Ruiz, Duncan R McKenzie, Irene Del Molino Del Barrio, Mark Harries

Lancet Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon.
Patriek Jurrius, Thomas Green, Hans Garmo, Matthew Young, Massimiliano Cariati, Mark Harries

Breast· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile.
Simon E Ward, Mark H Harries, Laura Aldegheri, Andrea M Bradford, Elisa Ballini

J Psychopharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Helena M Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Mark Harries

Lancet· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [F] fluorodeoxyglucose and [F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging.
Gurdip K Azad, Benjamin P Taylor, Adrian Green, Ines Sandri, Angela Swampillai, Mark Harries

Eur J Nucl Med Mol Imaging· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
P G Corrie, A Marshall, P D Nathan, P Lorigan, M Gore, M Harries, Mark Harries

Ann Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Mark Harries

Nat Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
Florent Grange, Peter Mohr, Mark Harries, Rainer Ehness, Laure Benjamin

Melanoma Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: A retrospective and prospective observational study (MELABIS).
Mark Harries, Peter Mohr, Florent Grange, Rainer Ehness, Laure Benjamin

Int J Clin Pract· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.
Simon E Ward, Paul Beswick, Novella Calcinaghi, Lee A Dawson, Jane Gartlon, Mark H Harries

Br J Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK.
Leah Fink, Justyna Amelio, Mark Harries, Celeste Lebbe, Elisabeth Livingstone

Eur J Dermatol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin.
Louise Saul, Kristina M Ilieva, Heather J Bax, Panagiotis Karagiannis, Isabel Correa, Mark Harries

Sci Rep· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Mark Harries, Josep Malvehy, Céleste Lebbe, Louise Heron, Justyna Amelio

Eur J Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma.
Panagiotis Karagiannis, Federica Villanova, Debra H Josephs, Isabel Correa, Mieke Van Hemelrijck, Mark Harries

Oncoimmunology· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Saif S Ahmad, Wendi Qian, Sarah Ellis, Elaine Mason, Muhammad A Khattak, Mark Harries

Melanoma Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.
Kristina M Ilieva, Isabel Correa, Debra H Josephs, Panagiotis Karagiannis, Isioma U Egbuniwe, Mark Harries

Mol Cancer Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis